Gan & Lee Pharmaceuticals Co (SHSE:603087) EV-to-EBITDA : 34.44 (As of May. 29, 2025)

Gan & Lee Pharmaceuticals Co EV-to-EBITDA Chart

Gan & Lee Pharmaceuticals Co Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
EV-to-EBITDA		Get a 7-Day Free Trial					44.46	18.38	-36.50	49.70	27.15

Gan & Lee Pharmaceuticals Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBITDA	Get a 7-Day Free Trial															63.83	47.13	63.81	27.15	29.06

Competitive Comparison of Gan & Lee Pharmaceuticals Co's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Gan & Lee Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gan & Lee Pharmaceuticals Co's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gan & Lee Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gan & Lee Pharmaceuticals Co's EV-to-EBITDA falls into.

Gan & Lee Pharmaceuticals Co EV-to-EBITDA Calculation

Gan & Lee Pharmaceuticals Co's EV-to-EBITDA for today is calculated as:

Gan & Lee Pharmaceuticals Co's current Enterprise Value is ¥29,319 Mil.
Gan & Lee Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥851 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan & Lee Pharmaceuticals Co  (SHSE:603087) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Gan & Lee Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:

Gan & Lee Pharmaceuticals Co's share price for today is ¥55.11.
Gan & Lee Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Gan & Lee Pharmaceuticals Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gan & Lee Pharmaceuticals Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Gan & Lee Pharmaceuticals Co Business Description